Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 1,322 | 2,239 | 23,904 | 60,876 | 55,238 |
| Gross Profit | 1,322 | 2,239 | 23,904 | 60,876 | 55,238 |
| Operating Expenses | 44,233 | 40,314 | 52,822 | 74,269 | 34,681 |
| Operating Income | -42,911 | -38,075 | -28,918 | -13,393 | 20,557 |
| Interest Expense | 318 | 315 | 302 | 295 | 469 |
| Other Income | 9,124 | -3,803 | 10,504 | -3,457 | 30 |
| Pre-tax Income | -34,105 | -42,194 | -18,715 | -17,145 | 20,118 |
| Income Tax | N/A | N/A | 26 | N/A | N/A |
| Net Income Continuous | -34,105 | -42,194 | -18,741 | -17,145 | 20,118 |
| Net Income | $-34,105 | $-42,194 | $-18,741 | $-17,145 | $20,118 |
| EPS Basic Total Ops | -3.68 | -7.64 | -4.31 | -6.30 | 7.90 |
| EPS Basic Continuous Ops | -3.68 | -7.64 | -4.31 | -6.27 | 7.92 |
| EPS Diluted Total Ops | -3.68 | -7.64 | -4.31 | -6.30 | 7.40 |
| EPS Diluted Continuous Ops | -3.68 | -7.64 | -4.31 | -6.27 | 7.45 |
| EPS Diluted Before Non-Recurring Items | -3.68 | -7.64 | -6.10 | -6.30 | N/A |
| EBITDA(a) | $-38,355 | $-34,330 | $-25,626 | $-11,740 | $21,105 |